Patient-Centered Dosing Initiative

Learn more and get involved with our collaborative projects to educate stakeholders, advance research, and connect people to resources that can improve outcomes.

Patient-Centered Dosing Initiative

Advocating for a better quality of life for people living with Metastatic Breast Cancer through Patient-Centered Dosing.


A poster was presented at JADPRO Live 2023, the Annual Meeting of the Advanced Practitioner Society for Hematology and Oncology (APSHO), highlighting the results from the Patient Survey – suggesting actions to improve patient-caregiver communication.

About the Patient-Centered Dosing Initiative (PCDI)

The PCDI, which consists of patient advocates and an Advisory Board of Medical Oncologists, encourages physicians and patients to jointly discuss dosages upon treatment initiation and throughout treatment, taking into account the patient’s personal wishes and unique characteristics such as age, availability of at-home care, history of side effects and more. Most MBC treatments are generally provided in a range of dosages.  When starting a treatment, patients are usually placed on the standard (highest) dose – which can cause the most side effects.

Once a patient experiences significant side effects, their doctor may reduce the dose or frequency of the treatment to ease the patient’s side effects.  Although additional data is warranted, recent evidence regarding several MBC drugs has shown that prescribing approved reduced drug doses may not decrease effectiveness.

Contributions by PCDI patient advocates include:

click here to learn more


(hover over or click on individual photos for identification)